Lam Le
BMT Group (Netherlands)(NL)Janssen (Netherlands)(NL)
Publications by Year
Research Areas
Respiratory viral infections research, Viral gastroenteritis research and epidemiology, SARS-CoV-2 and COVID-19 Research, Influenza Virus Research Studies, Pneumonia and Respiratory Infections
Most-Cited Works
- → Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials(2017)300 cited
- → Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study(2019)125 cited
- → An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults(2023)92 cited
- → Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial(2021)63 cited
- → Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions(2022)51 cited
- → Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer(2024)30 cited
- → A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses(2024)18 cited
- → Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G(2024)13 cited
- → Universal paramyxovirus vaccine design by stabilizing regions involved in structural transformation of the fusion protein(2024)11 cited
- → Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies(2024)3 cited